Logo

American Heart Association

  8
  0


Final ID: MDP230

Clinical and Hemodynamic Predictors of Stabilization and Associated Complications in Patients with Cardiogenic Shock Supported with Impella 5.5

Abstract Body (Do not enter title and authors here): Background: Despite widespread use of the Impella 5.5 to support patients with cardiogenic shock (CS), the identification of patient profiles that benefit the most from this intervention remains a challenge. Understanding the clinical and hemodynamic characteristics associated with successful outcomes is crucial for optimizing patient selection and management.
Methods: Using data from a comprehensive registry of 508 patients, we evaluated clinical stabilization among those receiving Impella 5.5 for CS. Clinical stabilization was defined as weaning from the Impella 5.5 without escalation to additional mechanical circulatory support and discharge from the hospital alive, or bridging to durable heart replacement therapy (HT or LVAD) without further escalation of support.
Results: Of the 508 patients analyzed, 30.7%(N=156) achieved clinical stabilization. The mean age of the cohort was 58.4±12.6 years, with 83.7% being male. Heart failure-related cardiogenic shock (HF-CS) was present in 69.5% of the patients. No significant demographic differences were observed between the stabilization and deterioration groups (p>0.05). Patients who stabilized were more likely to have HF-CS (p<0.001) and lower incidence of out-of-hospital cardiac arrest (OHCA)(p<0.001). Higher pulmonary artery pressure (mPAP, p=0.02) and pulmonary capillary wedge pressure (PCWP, p<0.001) were significant predictors of stabilization. The presence of implantable cardioverter-defibrillators (ICDs) was more common in stabilized patients (p=0.01). Major complications such as stroke (stabilization:3.8%, deterioration:6.1%, p=0.3), limb ischemia (stabilization:1.9%, deterioration:7.4%, p=0.02), and bleeding requiring surgery (stabilization:7.7%, deterioration:12.8%, p=0.09) were observed. Notably, bleeding requiring transfusion was significantly higher in the deterioration group (41.5% vs. 30.1%,p=0.02). The median duration from Impella 5.5 insertion to heart recovery or discharge was 15.1 days (IQR:7.7-29.1 days).
Conclusions: Among patients with CS supported with the Impella 5.5, those with HF-CS, higher pulmonary pressures, and the presence of ICDs are more likely to achieve clinical stabilization. Significant complications, including bleeding and limb ischemia, remain a concern and require careful management. This study highlights the importance of detailed pre-implant hemodynamic assessment and suggests that targeted management strategies based on these predictors could improve patient outcomes.
  • Blumer, Vanessa  ( Inova Schar Heart and Vascular , Arliton , Virginia , United States )
  • Abraham, Jacob  ( Providence Heart Institute , Portland , Oregon , United States )
  • Li, Borui  ( TUFTS MEDICAL CTR , Boston , Massachusetts , United States )
  • Kanwar, Manreet  ( Allegheny Health Network , Pittsburgh , Pennsylvania , United States )
  • Garan, Reshad  ( Beth Israel Deaconess Medical Cente , Boston , Massachusetts , United States )
  • Sinha, Shashank  ( Inova Schar Heart and Vascular , Fairfax , Virginia , United States )
  • Hernandez-montfort, Jaime  ( BSW , Temple , Texas , United States )
  • Burkhoff, Daniel  ( Cardiovascular Research Foundation , Remsenburg , New York , United States )
  • Kapur, Navin  ( TUFTS MEDICAL CTR , Boston , Massachusetts , United States )
  • Author Disclosures:
    Vanessa Blumer: DO NOT have relevant financial relationships | Jacob Abraham: DO have relevant financial relationships ; Consultant:Johnson&Johnson:Active (exists now) ; Consultant:AdonaMed:Past (completed) ; Consultant:FIRE!:Active (exists now) ; Speaker:Abbott:Past (completed) ; Speaker:Johnson&Johnson:Active (exists now) | Borui Li: No Answer | Manreet Kanwar: DO have relevant financial relationships ; Consultant:Abbott:Active (exists now) ; Speaker:Abiomed:Active (exists now) ; Consultant:BiVACOR:Active (exists now) ; Consultant:CorWave:Active (exists now) ; Consultant:Abiomed:Active (exists now) | Reshad Garan: No Answer | Shashank Sinha: DO NOT have relevant financial relationships | Jaime Hernandez-Montfort: DO NOT have relevant financial relationships | Daniel Burkhoff: DO have relevant financial relationships ; Other (please indicate in the box next to the company name):Ancora Heart - Institutional Support:Active (exists now) ; Consultant:Orchestra Biomedical:Active (exists now) ; Consultant:Corvia Medical:Active (exists now) ; Consultant:Aquaapass:Active (exists now) | Navin Kapur: No Answer
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Demystifying Disease Management in Heart Failure

Saturday, 11/16/2024 , 09:30AM - 10:45AM

Moderated Digital Poster Session

More abstracts on this topic:
Catastrophic Bioprosthetic Aortic Valve Thrombosis: An Unappreciated Complication of Veno-Arterial Extracorporeal Membrane Oxygenation Support in Cardiogenic Shock

O'hara Patrick, Heid Christopher, Lahsaei Peiman, Farr Maryjane, Garg Sonia, Araj Faris, Truby Lauren, Goral Montana, Kim Han, Malensek Paris, Beaini Hadi, Patel Ravi, Jawaid Anas, Hussain Fizza

Assessing the Clinical Impact of Cardiac Intensivists in Cardiac Intensive Care Units.: Results from the RESCUE registry

Bae Dae-hwan, Bae Jang-whan, Lee Junyoung, Sun Jonghee, Lee Sang Yeub, Yang Jeong Hoon, Gwon Hyeon-cheol

More abstracts from these authors:
The Pulmonary Resistance-Compliance Relationship: Real or Mathematical Artefact?

Hungerford Sara, Kapur Navin, Rich Stuart, Burkhoff Daniel

Re-Exploration of the Pulmonary Resistance-Compliance Relationship: a Universal Time Constant and Hyperbolic Fit?

Hungerford Sara, Adji Audrey, Kempton Hannah, Kapur Navin, Burkhoff Daniel

You have to be authorized to contact abstract author. Please, Login
Not Available